Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltrationMarko Škrtić, David Z.I. Cherney, Gary K. Yang et al.|Diabetologia|2014Cited by 162
Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the <scp>EMPA‐REG OUTCOME</scp> trial with a focus on AsiaQiuhe Ji, Odd Erik Johansen, Jyothis T. George et al.|Diabetes Obesity and Metabolism|2021Cited by 25
Erratum to: Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltrationMarko Škrtić, David Z.I. Cherney, Melvin Silverman et al.|Diabetologia|2017Cited by 0